joe•iuculano Jul 2, 2024

Via #CNN

The US #FoodAndDrugAdministration on Tuesday approved #donanemab, a #MonoclonalAntibody designed to slow the progression of early symptomatic #Alzheimer’s disease

Donanemab, made by #Indianapolis-based #EliLilly, works by helping body remove #AmyloidPlaque buildup in the brain, a hallmark of Alzheimer’s disease

It will be sold under the name #Kisunla and would cost $695/vial b4 insurance, what would amount to $12,522 for a 6-month course

#FDA

https://www.cnn.com/2024/07/02/health/lilly-azheimers-donanemab-fda/index.html

FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease

The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.

CNN